Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 124

Results For "Pharma"

3750 News Found

Torrent Pharmaceuticals Q1FY22 consolidated PAT up at Rs. 330 Cr
News | July 28, 2021

Torrent Pharmaceuticals Q1FY22 consolidated PAT up at Rs. 330 Cr

The company posted net profit of Rs.321 crores for the period ended June 30, 2020.


Sun Pharma signs Cassiopea for license and supply agreements
News | July 27, 2021

Sun Pharma signs Cassiopea for license and supply agreements

Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older


Sun Pharma Advanced Research Company Q1FY22 loss at Rs. 61.37 Cr
News | July 27, 2021

Sun Pharma Advanced Research Company Q1FY22 loss at Rs. 61.37 Cr

The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.


Alembic Pharmaceuticals Q1FY22 net slides to Rs. 164.52 Cr
News | July 27, 2021

Alembic Pharmaceuticals Q1FY22 net slides to Rs. 164.52 Cr

The US business faced price erosion due to increased competition.


Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr
News | July 22, 2021

Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr

The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.


Balaxi Pharmaceuticals Q1 revenue increases by 12%
News | July 20, 2021

Balaxi Pharmaceuticals Q1 revenue increases by 12%

The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY


Lonza extends collaboration with Biopharma company
News | July 19, 2021

Lonza extends collaboration with Biopharma company

As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies


Marksans Pharma shareholders vote for warrants worth Rs. 365 Cr
News | July 11, 2021

Marksans Pharma shareholders vote for warrants worth Rs. 365 Cr

The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant


Kwality Pharmaceuticals Q4FY21 consolidated PAT higher at Rs. 8.14 Cr
News | July 04, 2021

Kwality Pharmaceuticals Q4FY21 consolidated PAT higher at Rs. 8.14 Cr

The company reported total income of Rs.263.60 crores during the 12 months period ended March 31, 2021


Samrat Pharmachem reports Q4 FY21 PAT at Rs. 1.55 Cr
News | July 02, 2021

Samrat Pharmachem reports Q4 FY21 PAT at Rs. 1.55 Cr

The company has posted net profit / (loss) of Rs.5.33 crores for the 12 months period ended March 31, 2021